adenine has been researched along with Hypophosphatemia in 62 studies
Hypophosphatemia: A condition of an abnormally low level of PHOSPHATES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypophosphatemia linked to a decreased proximal tubular reabsorption was frequently observed in HIV-positive adults independently of the use of tenofovir." | 9.12 | Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? ( Badiou, S; Baillat, V; Cristol, JP; De Boever, CM; Reynes, J; Terrier, N, 2006) |
| " He had been receiving low-dose adefovir dipivoxil (ADV) for the treatment of lamivudine-resistant chronic hepatitis B virus infection for eight years and subsequently developed severe hypophosphatemia and proximal renal tubule dysfunction." | 8.90 | Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B. ( Eguchi, H; Hiromatsu, Y; Kuwahara, R; Tani, J; Tsuruta, M, 2014) |
| "To investigate the clinical features and treatment protocol and prognosis for the hypophosphataemic osteomalacia related to adefovir dipivoxil." | 8.87 | [A case of adefovir dipivoxil induced hypophosphataemic osteomalacia and literature review]. ( Li, XP; Meng, XW; Sun, XF; Xia, WB; Xing, XP; Zhang, HB, 2011) |
| "Adefovir dipivoxil (ADV) is one of the most important nucleostide analogues currently in use for the treatment of chronic hepatitis B virus (HBV) infection." | 7.91 | Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible? ( Dai, ZJ; Jin, J; Pan, YJ; Qian, YY; Ruan, LY; Shi, MT; Wu, CM; Zhu, YX, 2019) |
| " He had been receiving adefovir dipivoxil (ADV) for the treatment of entecavir (ETV)-resistant chronic hepatitis B (CHB) for four years in his 8-year treatment of hepatocellular carcinoma (HCC), but was referred to our hospital after increased levels of bone pain in his ribs, knees, and ankles." | 7.91 | [Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B]. ( Ikeda, A; Ikeda, F; Kanzaki, H; Kitamura, Y; Makita, T; Murakawa, K; Nishihara, S; Okada, H; Onishi, H; Sendo, T; Shiraha, H; Takaki, A; Takeuchi, Y; Tanaka, Y; Wada, N; Yasunaka, T, 2019) |
| " She had a 7-year history of taking adefovir at 10 mg/day for chronic hepatitis B." | 7.88 | Adefovir-induced Fanconi syndrome associated with osteomalacia. ( Cha, SK; Cho, DH; Kim, HS; Kim, JH; Kim, WI; Kim, YJ; Lee, EY; Lee, JH; Lee, SM; Park, KS; Park, S, 2018) |
| "To investigate the predictors of hypophosphatemic osteomalacia induced by adefovir dipivoxil (ADV) and to monitor for early detection." | 7.88 | Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil. ( Feng, L; Gao, RW; Li, R; Yang, YH; Zhang, B; Zhu, S; Zou, YZ, 2018) |
| "Retrieval of case reports was based on Pubmed, CNKI, Wan Fang and VIP databases using the key words adefovir dipivoxil, hypophosphatemia, osteomalacia and Fanconi syndrome." | 7.88 | Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series. ( Chen, N; Li, LY; Liu, LW; Peng, T; Tang, KX; Yu, F; Yu, X; Zhang, JB; Zhang, Q; Zhao, YP, 2018) |
| "Adefovir-induced hypophosphatemic osteomalacia in the context of hepatocarcinoma is rare and needs to be differentiated from metastatic hepatocarcinoma." | 7.85 | Adefovir-Induced Hypophosphatemic Osteomalacia Mimicking Bone Metastases From Primary Hepatocarcinoma. ( Luo, QY; Qiu, ZL; Shen, CT; Sun, ZK; Wei, WJ, 2017) |
| "Renal dysfunction and Fanconi's syndrome associated with hypophosphatemia caused by long-term administration of low-dose adefovir dipivoxil (ADV) has been reported in recent years." | 7.80 | Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M, 2014) |
| "In human immunodeficiency virus (HIV)-infected patients, tenofovir disoproxil fumarate (TDF) may cause hypophosphatemia leading to osteomalacia due to renal phosphate wasting." | 7.80 | Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia. ( Holmes, DT; Jiang, SY; Kendler, DL; Saeedi, R, 2014) |
| " Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin." | 7.79 | Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013) |
| "Occurrence of hypophosphatemic osteomalacia (HO) induced by administration of low-dose adefovir therapy is rare, and bone scintigraphy of the disease has rarely been reported." | 7.79 | Bone scintigraphic findings of hypophosphatemic osteomalacia associated with adefovir therapy: involvement of lower extremity skeletons. ( Ahn, BC; Kim, DH; Kweon, YO; Lee, J; Lee, SW, 2013) |
| "With the increasing use of tenofovir disoproxil in the management of HIV and hepatitis B, serious adverse effects, such as renal dysfunction, will inevitably increase in frequency." | 7.78 | Severe vitamin D deficiency in a patient treated for hepatitis B with tenofovir. ( Bower, M; Kumar, N; Nelson, M, 2012) |
| "Adefovir dipivoxil is commonly used for treatment of chronic hepatitis B." | 7.77 | [Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B]. ( Dong, GF; Li, L; Xie, YS; Zhang, X, 2011) |
| "The antiretroviral agent tenofovir can cause hypophosphatemic osteomalacia due to renal phosphate wasting." | 7.77 | Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. ( Boissier, MC; Prendki, V; Prie, D; Saidenberg-Kermanac'h, N; Souabni, L, 2011) |
| "We report two cases in which osteomalacia developed in patients on tenofovir-containing highly active antiretroviral therapy (HAART) in the context of Fanconi syndrome with hypophosphataemia." | 7.73 | The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. ( Issa, BG; Parsonage, MJ; Savage, MW; Snowden, N; Wilkins, EG, 2005) |
| "Tenofovir disoproxil fumarate (TDF) has been anecdotally associated with isolated hypophosphatemia (HP) as well as proximal tubular toxicity and renal dysfunction in which HP has consistently been a feature." | 7.73 | Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. ( Bannister, A; Day, SL; Fisher, M; Hankins, M; Leake Date, HA, 2005) |
| " Separate pharmacokinetic properties may be associated with distinct TDF toxicities: tenofovir with parathyroid hormone and altered calcium balance and tenofovir diphosphate with hypophosphatemia and FGF23 regulation." | 6.78 | Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? ( Baker, A; Bethel, J; Flynn, PM; Gordon, CM; Havens, PL; Hazra, R; Kapogiannis, BG; Kiser, JJ; Liu, N; Lujan-Zilbermann, J; Mulligan, K; Pan, CG; Rutledge, B; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR, 2013) |
| "Osteomalacia is a metabolic bone disease that leads to softening of the bones and can be caused by hypophosphatemia." | 6.49 | Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. ( Kim, du H; Min, YK; Sung, DH, 2013) |
| "Adefovir dipivoxil (ADV) is an acyclic nucleotide phosphate analogue, currently used for anti-HBV therapy." | 5.39 | [Hypophosphatemia and chest pain related to adefovir dipivoxil treatment for chronic hepatitis B: report of two cases]. ( Chen, Y; Liu, Z, 2013) |
| "Hypophosphatemic osteomalacia and renal Fanconi syndrome can be associated with low-dose ADV." | 5.39 | Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition. ( Dai, Z; Gu, X; Qian, Y; Wang, L; Wu, C; Zhang, H, 2013) |
| "Hypophosphatemia linked to a decreased proximal tubular reabsorption was frequently observed in HIV-positive adults independently of the use of tenofovir." | 5.12 | Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? ( Badiou, S; Baillat, V; Cristol, JP; De Boever, CM; Reynes, J; Terrier, N, 2006) |
| " He had been receiving low-dose adefovir dipivoxil (ADV) for the treatment of lamivudine-resistant chronic hepatitis B virus infection for eight years and subsequently developed severe hypophosphatemia and proximal renal tubule dysfunction." | 4.90 | Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B. ( Eguchi, H; Hiromatsu, Y; Kuwahara, R; Tani, J; Tsuruta, M, 2014) |
| "To investigate the clinical features and treatment protocol and prognosis for the hypophosphataemic osteomalacia related to adefovir dipivoxil." | 4.87 | [A case of adefovir dipivoxil induced hypophosphataemic osteomalacia and literature review]. ( Li, XP; Meng, XW; Sun, XF; Xia, WB; Xing, XP; Zhang, HB, 2011) |
| " He had been receiving adefovir dipivoxil (ADV) for the treatment of entecavir (ETV)-resistant chronic hepatitis B (CHB) for four years in his 8-year treatment of hepatocellular carcinoma (HCC), but was referred to our hospital after increased levels of bone pain in his ribs, knees, and ankles." | 3.91 | [Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B]. ( Ikeda, A; Ikeda, F; Kanzaki, H; Kitamura, Y; Makita, T; Murakawa, K; Nishihara, S; Okada, H; Onishi, H; Sendo, T; Shiraha, H; Takaki, A; Takeuchi, Y; Tanaka, Y; Wada, N; Yasunaka, T, 2019) |
| "Although denosumab is not generally an appropriate treatment for acquired Fanconi syndrome, it may be useful for patients who have hypophosphatemic osteomalacia due to adefovir dipivoxil-induced Fanconi syndrome associated with excessive bone resorption." | 3.91 | Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report. ( Aso, Y; Iijima, T; Jojima, T; Kase, M; Kogai, T; Kunii, T; Sakurai, S; Shimizu, M; Usui, I, 2019) |
| "Adefovir dipivoxil (ADV) is one of the most important nucleostide analogues currently in use for the treatment of chronic hepatitis B virus (HBV) infection." | 3.91 | Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible? ( Dai, ZJ; Jin, J; Pan, YJ; Qian, YY; Ruan, LY; Shi, MT; Wu, CM; Zhu, YX, 2019) |
| " She had a 7-year history of taking adefovir at 10 mg/day for chronic hepatitis B." | 3.88 | Adefovir-induced Fanconi syndrome associated with osteomalacia. ( Cha, SK; Cho, DH; Kim, HS; Kim, JH; Kim, WI; Kim, YJ; Lee, EY; Lee, JH; Lee, SM; Park, KS; Park, S, 2018) |
| "To investigate the predictors of hypophosphatemic osteomalacia induced by adefovir dipivoxil (ADV) and to monitor for early detection." | 3.88 | Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil. ( Feng, L; Gao, RW; Li, R; Yang, YH; Zhang, B; Zhu, S; Zou, YZ, 2018) |
| "Retrieval of case reports was based on Pubmed, CNKI, Wan Fang and VIP databases using the key words adefovir dipivoxil, hypophosphatemia, osteomalacia and Fanconi syndrome." | 3.88 | Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series. ( Chen, N; Li, LY; Liu, LW; Peng, T; Tang, KX; Yu, F; Yu, X; Zhang, JB; Zhang, Q; Zhao, YP, 2018) |
| "Adefovir-induced hypophosphatemic osteomalacia in the context of hepatocarcinoma is rare and needs to be differentiated from metastatic hepatocarcinoma." | 3.85 | Adefovir-Induced Hypophosphatemic Osteomalacia Mimicking Bone Metastases From Primary Hepatocarcinoma. ( Luo, QY; Qiu, ZL; Shen, CT; Sun, ZK; Wei, WJ, 2017) |
| "In human immunodeficiency virus (HIV)-infected patients, tenofovir disoproxil fumarate (TDF) may cause hypophosphatemia leading to osteomalacia due to renal phosphate wasting." | 3.80 | Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia. ( Holmes, DT; Jiang, SY; Kendler, DL; Saeedi, R, 2014) |
| "Renal dysfunction and Fanconi's syndrome associated with hypophosphatemia caused by long-term administration of low-dose adefovir dipivoxil (ADV) has been reported in recent years." | 3.80 | Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. ( Akuta, N; Arase, Y; Hara, T; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y; Tanaka, M, 2014) |
| " Of all the patients, 15 were diagnosed as tumor-induced HO, 4 were long-term oral adefovir dipivoxil-related HO, 3 were associated with Fanconi syndrome, 2 were related to hyperparathyroidism, while 2 were Sjogren's syndrome complicated with renal tubular acidosis." | 3.80 | [The clinical characteristics of 26 cases of hypophosphatemia osteomalacia misdiagnosed as spondyloarthritis]. ( Feng, L; Huang, F; Jin, J; Luo, G; Ma, H; Sun, F; Wang, G; Wang, Y; Yang, J; Zhang, J; Zhao, W; Zhao, Z; Zhu, J, 2014) |
| " Treatment of chronic hepatitis C in patients coinfected with HIV is a complex problem associated with toxicities and drug interactions between HIV antiretrovirals and interferon and ribavirin." | 3.79 | Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. ( Funk, EK; Heytens, L; Kohli, A; Kottilil, S; Kwan, R; Masur, H; Nelson, A; Polis, MA; Shaffer, A; Shivakumar, B; Sneller, M, 2013) |
| "Occurrence of hypophosphatemic osteomalacia (HO) induced by administration of low-dose adefovir therapy is rare, and bone scintigraphy of the disease has rarely been reported." | 3.79 | Bone scintigraphic findings of hypophosphatemic osteomalacia associated with adefovir therapy: involvement of lower extremity skeletons. ( Ahn, BC; Kim, DH; Kweon, YO; Lee, J; Lee, SW, 2013) |
| "With the increasing use of tenofovir disoproxil in the management of HIV and hepatitis B, serious adverse effects, such as renal dysfunction, will inevitably increase in frequency." | 3.78 | Severe vitamin D deficiency in a patient treated for hepatitis B with tenofovir. ( Bower, M; Kumar, N; Nelson, M, 2012) |
| "The antiretroviral agent tenofovir can cause hypophosphatemic osteomalacia due to renal phosphate wasting." | 3.77 | Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease. ( Boissier, MC; Prendki, V; Prie, D; Saidenberg-Kermanac'h, N; Souabni, L, 2011) |
| "Adefovir dipivoxil is commonly used for treatment of chronic hepatitis B." | 3.77 | [Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B]. ( Dong, GF; Li, L; Xie, YS; Zhang, X, 2011) |
| "Adefovir dipivoxil, an acyclic nucleoside analogue, has been approved for the treatment of patients with chronic hepatitis B." | 3.76 | [A case of osteomalacia related to adefovir in a patient with chronic hepatitis B]. ( Ahn, SY; Choe, WH; Choi, YH; Jang, YM; Kim, BK; Ko, SY; Kwon, SY; Lee, CH, 2010) |
| "We report two cases in which osteomalacia developed in patients on tenofovir-containing highly active antiretroviral therapy (HAART) in the context of Fanconi syndrome with hypophosphataemia." | 3.73 | The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. ( Issa, BG; Parsonage, MJ; Savage, MW; Snowden, N; Wilkins, EG, 2005) |
| "Tenofovir disoproxil fumarate (TDF) has been anecdotally associated with isolated hypophosphatemia (HP) as well as proximal tubular toxicity and renal dysfunction in which HP has consistently been a feature." | 3.73 | Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. ( Bannister, A; Day, SL; Fisher, M; Hankins, M; Leake Date, HA, 2005) |
| " Separate pharmacokinetic properties may be associated with distinct TDF toxicities: tenofovir with parathyroid hormone and altered calcium balance and tenofovir diphosphate with hypophosphatemia and FGF23 regulation." | 2.78 | Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? ( Baker, A; Bethel, J; Flynn, PM; Gordon, CM; Havens, PL; Hazra, R; Kapogiannis, BG; Kiser, JJ; Liu, N; Lujan-Zilbermann, J; Mulligan, K; Pan, CG; Rutledge, B; Stephensen, CB; Van Loan, MD; Wilson, CM; Woodhouse, LR, 2013) |
| " HIV serostatus, clinical and laboratory adverse events (AEs), adherence (pill count, Medication Event Monitoring System, and self-report), and sexual and other sociobehavioral data were assessed at 3-month intervals for 24 months." | 2.78 | Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. ( Ackers, ML; Buchbinder, SP; Chillag, KL; Collins, BM; Grant, RM; Grohskopf, LA; Gvetadze, R; Liu, AY; Mayer, KH; Oʼhara, B; Pathak, SR; Paxton, LA; Rose, CE; Thompson, M, 2013) |
| "Osteomalacia is a metabolic bone disease that leads to softening of the bones and can be caused by hypophosphatemia." | 2.49 | Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. ( Kim, du H; Min, YK; Sung, DH, 2013) |
| "He had been diagnosed with diabetic kidney disease and osteomalacia due to vitamin D deficiency; thus, ADV was not discontinued until he was referred to us." | 1.51 | Hypophosphatemic Osteomalacia Associated with Adefovir-induced Fanconi Syndrome Initially Diagnosed as Diabetic Kidney Disease and Vitamin D Deficiency. ( Iino, N; Koda, R; Narita, I; Tsuchida, M, 2019) |
| "Acquired Fanconi syndrome has been associated with the long-term ingestion of several nucleoside analogs used to treat chronic hepatitis B virus infection." | 1.51 | A case of entecavir-induced Fanconi syndrome. ( Fujii, T; Kawasoe, K; Nitta, K; Ohta, A, 2019) |
| "Adefovir dipivoxil (ADV) is an acyclic nucleotide phosphate analogue, currently used for anti-HBV therapy." | 1.39 | [Hypophosphatemia and chest pain related to adefovir dipivoxil treatment for chronic hepatitis B: report of two cases]. ( Chen, Y; Liu, Z, 2013) |
| "Hypophosphatemic osteomalacia and renal Fanconi syndrome can be associated with low-dose ADV." | 1.39 | Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition. ( Dai, Z; Gu, X; Qian, Y; Wang, L; Wu, C; Zhang, H, 2013) |
| "Despite the recent publication of case reports describing various manifestations of tenofovir-related nephrotoxicity, data regarding the incidence of and risk factors for this adverse effect are currently lacking." | 1.33 | Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. ( Antoniou, T; Chirhin, S; Gough, K; Govan, V; Loutfy, M; Raboud, J; Rachlis, A; Yoong, D, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.61) | 18.2507 |
| 2000's | 14 (22.58) | 29.6817 |
| 2010's | 42 (67.74) | 24.3611 |
| 2020's | 5 (8.06) | 2.80 |
| Authors | Studies |
|---|---|
| Alhamoudi, KM | 1 |
| Alghamdi, B | 1 |
| Alswailem, M | 1 |
| Nasir, A | 1 |
| Aljomaiah, A | 1 |
| Al-Hindi, H | 1 |
| Alzahrani, AS | 1 |
| Leungsuwan, S | 1 |
| Hooi, B | 1 |
| Myint, KS | 1 |
| Sun, L | 1 |
| Yi, D | 1 |
| Sun, W | 1 |
| Wang, C | 1 |
| Dong, X | 1 |
| Chen, X | 1 |
| Tian, Y | 1 |
| Wang, J | 1 |
| López Medina, JA | 1 |
| Simón Frapolli, VJ | 1 |
| Tinahones Madueño, FJ | 1 |
| Wei, WJ | 1 |
| Sun, ZK | 1 |
| Shen, CT | 1 |
| Qiu, ZL | 1 |
| Luo, QY | 1 |
| Park, S | 1 |
| Kim, WI | 1 |
| Cho, DH | 1 |
| Kim, YJ | 1 |
| Kim, HS | 1 |
| Kim, JH | 1 |
| Cha, SK | 1 |
| Park, KS | 1 |
| Lee, JH | 1 |
| Lee, SM | 1 |
| Lee, EY | 1 |
| Zhu, S | 1 |
| Yang, YH | 1 |
| Gao, RW | 1 |
| Li, R | 1 |
| Zou, YZ | 1 |
| Feng, L | 2 |
| Zhang, B | 1 |
| Chen, N | 1 |
| Zhang, JB | 1 |
| Zhang, Q | 1 |
| Zhao, YP | 1 |
| Li, LY | 1 |
| Liu, LW | 1 |
| Yu, F | 1 |
| Yu, X | 1 |
| Peng, T | 1 |
| Tang, KX | 1 |
| Koda, R | 1 |
| Tsuchida, M | 1 |
| Iino, N | 1 |
| Narita, I | 1 |
| Lv, Y | 1 |
| Li, X | 1 |
| Liang, S | 1 |
| Liang, D | 1 |
| Xu, F | 1 |
| Zhu, X | 1 |
| Zeng, C | 1 |
| Makita, T | 1 |
| Kanzaki, H | 1 |
| Onishi, H | 1 |
| Ikeda, A | 1 |
| Takaki, A | 1 |
| Wada, N | 1 |
| Takeuchi, Y | 1 |
| Yasunaka, T | 1 |
| Ikeda, F | 1 |
| Shiraha, H | 1 |
| Tanaka, Y | 1 |
| Nishihara, S | 1 |
| Murakawa, K | 1 |
| Kitamura, Y | 1 |
| Okada, H | 1 |
| Sendo, T | 1 |
| Kunii, T | 1 |
| Iijima, T | 1 |
| Jojima, T | 1 |
| Shimizu, M | 1 |
| Kase, M | 1 |
| Sakurai, S | 1 |
| Kogai, T | 1 |
| Usui, I | 1 |
| Aso, Y | 1 |
| Qian, YY | 1 |
| Dai, ZJ | 1 |
| Ruan, LY | 1 |
| Pan, YJ | 1 |
| Jin, J | 2 |
| Shi, MT | 1 |
| Zhu, YX | 1 |
| Wu, CM | 1 |
| Fujii, T | 1 |
| Kawasoe, K | 1 |
| Ohta, A | 1 |
| Nitta, K | 1 |
| Grohskopf, LA | 1 |
| Chillag, KL | 1 |
| Gvetadze, R | 1 |
| Liu, AY | 1 |
| Thompson, M | 1 |
| Mayer, KH | 1 |
| Collins, BM | 1 |
| Pathak, SR | 1 |
| Oʼhara, B | 1 |
| Ackers, ML | 1 |
| Rose, CE | 1 |
| Grant, RM | 1 |
| Paxton, LA | 1 |
| Buchbinder, SP | 1 |
| Kim, DH | 1 |
| Lee, SW | 1 |
| Kweon, YO | 1 |
| Lee, J | 1 |
| Ahn, BC | 1 |
| Tanaka, M | 1 |
| Suzuki, F | 1 |
| Seko, Y | 1 |
| Hara, T | 1 |
| Kawamura, Y | 1 |
| Sezaki, H | 1 |
| Hosaka, T | 1 |
| Akuta, N | 1 |
| Kobayashi, M | 2 |
| Suzuki, Y | 1 |
| Saitoh, S | 1 |
| Arase, Y | 1 |
| Ikeda, K | 2 |
| Kumada, H | 2 |
| Ichchou, L | 1 |
| Rist, S | 1 |
| Lespessailles, E | 1 |
| Prié, D | 3 |
| Benhamou, CL | 1 |
| Wu, C | 1 |
| Zhang, H | 1 |
| Qian, Y | 1 |
| Wang, L | 1 |
| Gu, X | 1 |
| Dai, Z | 1 |
| Funk, EK | 1 |
| Shaffer, A | 1 |
| Shivakumar, B | 1 |
| Sneller, M | 1 |
| Polis, MA | 1 |
| Masur, H | 1 |
| Heytens, L | 1 |
| Nelson, A | 1 |
| Kwan, R | 1 |
| Kottilil, S | 1 |
| Kohli, A | 1 |
| Wainwright, E | 1 |
| Sherrard, J | 1 |
| Duncan, S | 1 |
| Shine, B | 1 |
| Dorrell, L | 1 |
| Bickel, M | 1 |
| Khaykin, P | 1 |
| Stephan, C | 1 |
| Schmidt, K | 1 |
| Buettner, M | 1 |
| Amann, K | 1 |
| Lutz, T | 1 |
| Gute, P | 1 |
| Haberl, A | 1 |
| Geiger, H | 1 |
| Brodt, HR | 1 |
| Jung, O | 1 |
| Havens, PL | 1 |
| Kiser, JJ | 1 |
| Stephensen, CB | 1 |
| Hazra, R | 1 |
| Flynn, PM | 1 |
| Wilson, CM | 1 |
| Rutledge, B | 1 |
| Bethel, J | 1 |
| Pan, CG | 1 |
| Woodhouse, LR | 1 |
| Van Loan, MD | 1 |
| Liu, N | 1 |
| Lujan-Zilbermann, J | 1 |
| Baker, A | 1 |
| Kapogiannis, BG | 1 |
| Gordon, CM | 1 |
| Mulligan, K | 1 |
| Liu, Z | 1 |
| Chen, Y | 1 |
| Eguchi, H | 1 |
| Tsuruta, M | 1 |
| Tani, J | 1 |
| Kuwahara, R | 1 |
| Hiromatsu, Y | 1 |
| Hamnvik, OP | 1 |
| Becker, CB | 1 |
| Levy, BD | 1 |
| Loscalzo, J | 1 |
| Saeedi, R | 1 |
| Jiang, SY | 1 |
| Holmes, DT | 1 |
| Kendler, DL | 1 |
| Hirose, K | 1 |
| Ubara, Y | 1 |
| Hiramatsu, R | 1 |
| Sawa, N | 1 |
| Hasegawa, E | 1 |
| Takaichi, K | 1 |
| Murakami, M | 1 |
| Maggi, P | 1 |
| Montinaro, V | 1 |
| Leone, A | 1 |
| Fasano, M | 1 |
| Volpe, A | 1 |
| Bellacosa, C | 1 |
| Grattagliano, V | 1 |
| Coladonato, L | 1 |
| Lapadula, G | 1 |
| Santantonio, T | 1 |
| Angarano, G | 1 |
| Lin, Q | 1 |
| Pan, F | 1 |
| Hong, F | 1 |
| Pan, C | 1 |
| Sun, F | 1 |
| Wang, G | 1 |
| Yang, J | 1 |
| Luo, G | 1 |
| Ma, H | 1 |
| Zhao, Z | 1 |
| Wang, Y | 1 |
| Zhao, W | 1 |
| Zhang, J | 1 |
| Zhu, J | 1 |
| Huang, F | 1 |
| Xu, LJ | 1 |
| Jiang, Y | 1 |
| Liao, RX | 1 |
| Zhang, HB | 2 |
| Mao, JF | 1 |
| Chi, Y | 1 |
| Li, M | 1 |
| Wang, O | 1 |
| Liu, XQ | 1 |
| Liu, ZY | 1 |
| Xing, XP | 2 |
| Yu, W | 1 |
| Xia, WB | 2 |
| Oh, HM | 1 |
| Oh, J | 1 |
| Kim, KT | 1 |
| Lee, JI | 1 |
| Libório, AB | 1 |
| Andrade, L | 1 |
| Pereira, LV | 1 |
| Sanches, TR | 1 |
| Shimizu, MH | 1 |
| Seguro, AC | 1 |
| Lee, HJ | 1 |
| Choi, JW | 1 |
| Kim, TN | 1 |
| Eun, JR | 1 |
| Jaafar, A | 1 |
| Séronie-Vivien, S | 1 |
| Malard, L | 1 |
| Massip, P | 1 |
| Chatelut, E | 1 |
| Tack, I | 1 |
| Wood, SM | 1 |
| Shah, SS | 1 |
| Steenhoff, AP | 1 |
| Meyers, KE | 1 |
| Kaplan, BS | 1 |
| Rutstein, RM | 1 |
| Barril Cuadrado, G | 1 |
| de Los Santos Gil, I | 1 |
| Wong, T | 1 |
| Girgis, CM | 1 |
| Ngu, MC | 1 |
| Chen, RC | 1 |
| Emmett, L | 1 |
| Archer, KA | 1 |
| Seibel, MJ | 1 |
| Judd, A | 1 |
| Boyd, KL | 1 |
| Stöhr, W | 1 |
| Dunn, D | 1 |
| Butler, K | 1 |
| Lyall, H | 1 |
| Sharland, M | 1 |
| Shingadia, D | 1 |
| Riordan, A | 1 |
| Gibb, DM | 1 |
| Kwon, SY | 1 |
| Ahn, SY | 1 |
| Ko, SY | 1 |
| Jang, YM | 1 |
| Choi, YH | 1 |
| Kim, BK | 1 |
| Choe, WH | 1 |
| Lee, CH | 1 |
| Saidenberg-Kermanac'h, N | 1 |
| Souabni, L | 1 |
| Prendki, V | 1 |
| Boissier, MC | 1 |
| Pérez-Rivera, AÁ | 1 |
| Sáez, P | 1 |
| León, E | 1 |
| Lozano de León-Naranjo, F | 1 |
| Kawate, H | 1 |
| Taketomi, A | 1 |
| Watanabe, T | 1 |
| Nomura, M | 1 |
| Kato, M | 1 |
| Sakamoto, R | 1 |
| Ikegami, T | 1 |
| Soejima, Y | 1 |
| Maehara, Y | 1 |
| Takayanagi, R | 1 |
| Fabbriciani, G | 1 |
| de Socio, GV | 1 |
| Massarotti, M | 1 |
| Ceriani, R | 1 |
| Marasini, B | 1 |
| Li, L | 1 |
| Dong, GF | 1 |
| Zhang, X | 1 |
| Xie, YS | 1 |
| Sun, XF | 1 |
| Li, XP | 1 |
| Meng, XW | 1 |
| Kumar, N | 1 |
| Bower, M | 1 |
| Nelson, M | 1 |
| Bech, A | 1 |
| Van Bentum, P | 1 |
| Nabbe, K | 1 |
| Gisolf, J | 1 |
| Richter, C | 1 |
| De Boer, H | 1 |
| Schmid, H | 1 |
| Tokarska-Schlattner, M | 1 |
| Füeßl, B | 1 |
| Röder, M | 1 |
| Kay, L | 1 |
| Attia, S | 1 |
| Lederer, SR | 1 |
| Goebel, FD | 1 |
| Schlattner, U | 1 |
| Bogner, JR | 1 |
| Kim, du H | 1 |
| Sung, DH | 1 |
| Min, YK | 1 |
| Peyrière, H | 1 |
| Reynes, J | 2 |
| Rouanet, I | 1 |
| Daniel, N | 1 |
| de Boever, CM | 2 |
| Mauboussin, JM | 1 |
| Leray, H | 1 |
| Moachon, L | 1 |
| Vincent, D | 1 |
| Salmon-Céron, D | 1 |
| Breton, G | 1 |
| Alexandre, M | 1 |
| Duval, X | 1 |
| Peytavin, G | 1 |
| Leport, C | 1 |
| Vildei, JL | 1 |
| Day, SL | 1 |
| Leake Date, HA | 1 |
| Bannister, A | 1 |
| Hankins, M | 1 |
| Fisher, M | 1 |
| Antoniou, T | 1 |
| Raboud, J | 1 |
| Chirhin, S | 1 |
| Yoong, D | 1 |
| Govan, V | 1 |
| Gough, K | 1 |
| Rachlis, A | 1 |
| Loutfy, M | 1 |
| Fine, DM | 1 |
| Parsonage, MJ | 1 |
| Wilkins, EG | 1 |
| Snowden, N | 1 |
| Issa, BG | 1 |
| Savage, MW | 1 |
| Badiou, S | 1 |
| Terrier, N | 1 |
| Baillat, V | 1 |
| Cristol, JP | 1 |
| Buchacz, K | 1 |
| Brooks, JT | 1 |
| Tong, T | 1 |
| Moorman, AC | 1 |
| Baker, RK | 1 |
| Holmberg, SD | 1 |
| Greenberg, A | 1 |
| Roselló, L | 1 |
| Gort, A | 1 |
| Planella, R | 1 |
| Cabau, J | 1 |
| Baker, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir[NCT02588287] | 14 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370] | Phase 4 | 10 participants (Actual) | Interventional | 2018-01-08 | Completed | ||
| Randomized, Placebo-controlled Trial of the Safety and Effectiveness of Vitamin D Supplement to Improve Tubular Reabsorption of Phosphate and Decrease Bone Turnover in Adolescents and Young Adults With HIV Infection Being Treated With Antiretroviral Thera[NCT00490412] | 207 participants (Actual) | Interventional | 2007-12-31 | Completed | |||
| The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate[NCT05313477] | Phase 4 | 64 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | ||
| Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients[NCT00551655] | 684 participants (Actual) | Observational | 2007-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 3466 |
| TAF With a Boosted PI | 743 |
| TAF With a Boosted PI and LDV/SOF | 868 |
Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks
| Intervention | fmol/2x7mm punches (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 36014 |
| TAF With a Boosted PI | 6735 |
| TAF With a Boosted PI and LDV/SOF | 6100 |
Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks
| Intervention | fmol/10^6 cells (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 83.0 |
| TAF With a Boosted PI | 926 |
| TAF With a Boosted PI and LDV/SOF | 1129 |
Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
| Intervention | mL/min/1.73 m^2 (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 86.7 |
| TAF With a Boosted PI | 91.0 |
| TAF With a Boosted PI and LDV/SOF | 88.1 |
Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
| Intervention | mg/g (Geometric Mean) |
|---|---|
| TDF With a Boosted PI | 134 |
| TAF With a Boosted PI | 118 |
| TAF With a Boosted PI and LDV/SOF | 97.3 |
Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
| Intervention | ug/g (Geometric Mean) | |
|---|---|---|
| β2M:Cr ratio | RBP:Cr ratio | |
| TAF With a Boosted PI | 224 | 242 |
| TAF With a Boosted PI and LDV/SOF | 178 | 146 |
| TDF With a Boosted PI | 419 | 436 |
6 reviews available for adenine and Hypophosphatemia
| Article | Year |
|---|---|
Hypophosphatemic osteomalacia due to drug-induced Fanconi's syndrome associated with adefovir dipivoxil treatment for hepatitis B.
Topics: Adenine; Bone Diseases, Metabolic; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Hypophosphatemia; | 2014 |
Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.
Topics: Adenine; Adolescent; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or A | 2009 |
[Management of renal toxicity in HIV-positive patients. What to measure, how to measure it and how frequently].
Topics: Adenine; Algorithms; Anti-HIV Agents; beta 2-Microglobulin; Clinical Trials as Topic; Cohort Studies | 2008 |
[A case of adefovir dipivoxil induced hypophosphataemic osteomalacia and literature review].
Topics: Adenine; Humans; Hypophosphatemia; Male; Middle Aged; Organophosphonates; Osteomalacia | 2011 |
Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review.
Topics: Adenine; Bone and Bones; Dose-Response Relationship, Drug; Humans; Hypophosphatemia; Male; Middle Ag | 2013 |
Editorial comment: tenofovir nephrotoxicity--vigilance required.
Topics: Adenine; Fanconi Syndrome; Glycosuria; HIV Infections; Humans; Hypokalemia; Hypophosphatemia; Organo | 2005 |
3 trials available for adenine and Hypophosphatemia
53 other studies available for adenine and Hypophosphatemia
| Article | Year |
|---|---|
A Unique Mechanism of a Novel Synonymous PHEX Variant Causing X-Linked Hypophosphatemia.
Topics: Adenine; Amino Acids; Codon, Terminator; Cytosine; DNA, Complementary; Familial Hypophosphatemic Ric | 2022 |
Hypophosphatemic Osteomalacia Due to Adefovir-Induced Fanconi Syndrome.
Topics: Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Female; Hepatitis C, Chronic; Humans; Hy | 2020 |
Retrospective analysis of the clinical characteristics of adefovir dipivoxil-induced Fanconi's syndrome in the Chinese population.
Topics: Adenine; Adult; Aged; Alkaline Phosphatase; Asian People; Bone Density; Fanconi Syndrome; Female; Gl | 2020 |
Severe hypophosphataemic osteomalacia related to low-dose adefovir dipivoxil therapy in a hepatitis B virus patient.
Topics: Adenine; Antiviral Agents; Hepatitis B virus; Hepatitis B, Chronic; Humans; Hypophosphatemia; Organo | 2021 |
[Adefovir-induced osteomalacia and hypophosphatemia].
Topics: Adenine; Humans; Hypophosphatemia; Organophosphonates; Osteomalacia | 2022 |
Adefovir-Induced Hypophosphatemic Osteomalacia Mimicking Bone Metastases From Primary Hepatocarcinoma.
Topics: Adenine; Bone Neoplasms; Humans; Hypophosphatemia; Liver Neoplasms; Male; Middle Aged; Organophospho | 2017 |
Adefovir-induced Fanconi syndrome associated with osteomalacia.
Topics: Adenine; Adult; Bone and Bones; Fanconi Syndrome; Female; Fibroblast Growth Factor-23; Fibroblast Gr | 2018 |
Clinical features of hypophosphatemic osteomalacia induced by long-term low-dose adefovir dipivoxil.
Topics: Adenine; Adult; Aged; Alkaline Phosphatase; Biomarkers; China; Cross-Sectional Studies; Drug Monitor | 2018 |
Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Female; Hepatitis B, Chroni | 2018 |
Hypophosphatemic Osteomalacia Associated with Adefovir-induced Fanconi Syndrome Initially Diagnosed as Diabetic Kidney Disease and Vitamin D Deficiency.
Topics: Adenine; Aged; Antiviral Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diagnostic Error | 2019 |
The clinical and pathological features of adefovir dipivoxil-related renal impairment
.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Glycosuria; Hematuria; Hepatitis B, Chronic; H | 2019 |
[Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B].
Topics: Adenine; Aged; Carcinoma, Hepatocellular; Fanconi Syndrome; Fractures, Bone; Hepatitis B, Chronic; H | 2019 |
Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report.
Topics: Adenine; Adult; Antiviral Agents; Bone Density Conservation Agents; Denosumab; Fanconi Syndrome; Hep | 2019 |
Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible?
Topics: Adenine; Aged; Dose-Response Relationship, Drug; Fanconi Syndrome; Female; Hepatitis B, Chronic; Hum | 2019 |
A case of entecavir-induced Fanconi syndrome.
Topics: Acidosis; Acute Kidney Injury; Adenine; Aged; Alanine; Antiviral Agents; Fanconi Syndrome; Guanine; | 2019 |
Bone scintigraphic findings of hypophosphatemic osteomalacia associated with adefovir therapy: involvement of lower extremity skeletons.
Topics: Adenine; Bone and Bones; Humans; Hypophosphatemia; Lower Extremity; Male; Middle Aged; Organophospho | 2013 |
Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Creatinine; Drug Therapy, Combination; Female; Glomerular Fi | 2014 |
Reversible increase in FGF23 in a hypophosphatemic renal and bone disease linked to antiviral therapy by adefovir.
Topics: Adenine; Aged; Antiviral Agents; Bone Diseases; Female; Fibroblast Growth Factor-23; Fibroblast Grow | 2013 |
Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition.
Topics: Adenine; Antiviral Agents; Dose-Response Relationship, Drug; Fanconi Syndrome; Humans; Hypophosphate | 2013 |
Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Interactions; Drug Therapy, Com | 2013 |
Hypophosphataemia with non-tenofovir-containing antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Female; Glomerular Filtration Rate; | 2013 |
Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Inter | 2013 |
[Hypophosphatemia and chest pain related to adefovir dipivoxil treatment for chronic hepatitis B: report of two cases].
Topics: Adenine; Chest Pain; Female; Humans; Hypophosphatemia; Male; Middle Aged; Organophosphonates; Young | 2013 |
Clinical problem-solving. Wasting away.
Topics: Adenine; Adult; Bone Diseases, Metabolic; Cachexia; Diagnosis, Differential; Fanconi Syndrome; Femal | 2014 |
Fibroblast growth factor 23 is elevated in tenofovir-related hypophosphatemia.
Topics: Adenine; Adult; Anti-HIV Agents; Bone Density; Fanconi Syndrome; Fibroblast Growth Factor-23; Fibrob | 2014 |
[Case report; Fanconi's syndrome and hypophosphatemic osteomalacia associated with adefovir dipivoxil: a case report].
Topics: Adenine; Aged; Antiviral Agents; Fanconi Anemia; Humans; Hypophosphatemia; Organophosphonates; Osteo | 2014 |
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.
Topics: Adenine; Adult; Aged; Antiviral Agents; Bone Diseases; Drug-Related Side Effects and Adverse Reactio | 2015 |
[Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by adefovir in a patient with chronic hepatitis B].
Topics: Adenine; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Hypophosphatemia; Organophosphonates; Osteo | 2014 |
[The clinical characteristics of 26 cases of hypophosphatemia osteomalacia misdiagnosed as spondyloarthritis].
Topics: Adenine; Adult; Antirheumatic Agents; Biomarkers; C-Reactive Protein; Fanconi Syndrome; Female; Huma | 2014 |
Low-dose adefovir dipivoxil may induce Fanconi syndrome: clinical characteristics and long-term follow-up for Chinese patients.
Topics: Adenine; Adult; Alkaline Phosphatase; Antiviral Agents; Asian People; Bone Density; Creatinine; Drug | 2015 |
Osteomalacia as a Cause of Chronic Low Back and Buttock Pain.
Topics: Adenine; Adult; Antiviral Agents; Buttocks; Fractures, Spontaneous; Gait; Humans; Hypophosphatemia; | 2015 |
Rosiglitazone reverses tenofovir-induced nephrotoxicity.
Topics: Adenine; Animals; Drug-Related Side Effects and Adverse Reactions; Glomerular Filtration Rate; Hypog | 2008 |
[A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus].
Topics: Absorptiometry, Photon; Adenine; Adult; Antiviral Agents; Bone Density; DNA, Viral; Drug Resistance, | 2008 |
Urinary cystatin C can improve the renal safety follow-up of tenofovir-treated patients.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Creatinine; Cystatin C; Fanconi Syndrome; HIV Infections; Huma | 2009 |
Hypophosphatemic osteomalacia after low-dose adefovir dipivoxil therapy for hepatitis B.
Topics: Adenine; Adult; Antiviral Agents; Hepatitis B, Chronic; Humans; Hypophosphatemia; Magnetic Resonance | 2010 |
Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
Topics: Adenine; Adolescent; Anti-HIV Agents; Case-Control Studies; Child; Child, Preschool; England; Female | 2010 |
[A case of osteomalacia related to adefovir in a patient with chronic hepatitis B].
Topics: Adenine; Aged; Alkaline Phosphatase; Antiviral Agents; Dietary Supplements; DNA, Viral; Hepatitis B, | 2010 |
Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Drug Substitution; Fibroblast G | 2011 |
[HIV infected women with intense bone and muscular pain and general weakness].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combina | 2011 |
Hypophosphatemic osteomalacia as a long-term complication after liver transplantation.
Topics: Adenine; Aged; Fanconi Syndrome; Female; Humans; Hypophosphatemia; Immunosuppressive Agents; Liver T | 2011 |
Adefovir induced hypophosphatemic osteomalacia.
Topics: Adenine; Aged; Humans; Hypophosphatemia; Male; Organophosphonates; Osteomalacia; Radionuclide Imagin | 2011 |
[Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B].
Topics: Adenine; Antiviral Agents; Bone Diseases, Metabolic; Fanconi Syndrome; Hepatitis B, Chronic; Humans; | 2011 |
Severe vitamin D deficiency in a patient treated for hepatitis B with tenofovir.
Topics: Adenine; Hepatitis B; Humans; Hypophosphatemia; Male; Middle Aged; Organophosphonates; Reverse Trans | 2012 |
Fibroblast growth factor 23 in hypophosphataemic HIV-positive adults on tenofovir.
Topics: Adenine; Anti-HIV Agents; Calcium; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Fact | 2012 |
Macro CK2 accumulation in tenofovir-treated HIV patients is facilitated by CK oligomer stabilization but is not predictive for pathology.
Topics: Adenine; Anti-HIV Agents; Catalysis; Creatine Kinase, Mitochondrial Form; Enzyme Stability; Follow-U | 2013 |
Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.
Topics: Adenine; Adult; Anti-HIV Agents; Body Weight; Drug Therapy, Combination; Female; Glycosuria; Humans; | 2004 |
Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Topics: Adenine; Anti-HIV Agents; Drug Therapy, Combination; Fanconi Syndrome; HIV Infections; HIV-1; Humans | 2004 |
Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Chemical Analysis; Creatinine | 2005 |
Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Creatinine; Female; HIV Infections; Humans; Hypophosphatemia; Kidne | 2005 |
The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Fanconi Syndrome; Female; HIV Infec | 2005 |
Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Hypophosphate | 2006 |
[Hypophosphatemia and multiple fractures in patient with human immunodeficiency virus infection treated with tenofovir].
Topics: Adenine; Adult; Fractures, Bone; HIV Infections; Humans; Hypophosphatemia; Male; Organophosphonates; | 2007 |
Kidney dysfunction: a safety update on adefovir (preveon).
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Creatinine; Fanconi Syndrome; HIV Infections; Humans; Hy | 1998 |